Servi­er bags an an­ti­body spe­cial­ist in its lat­est on­col­o­gy M&A deal with plans to add the plat­form tech

What­ev­er Servi­er learned about Sym­phogen dur­ing their 2-year de­vel­op­ment al­liance must have sig­nif­i­cant­ly whet­ted their ap­petite for an ac­qui­si­tion.

Paris-based Servi­er an­nounced Fri­day that it has struck a deal to buy out the an­ti­body ex­pert. The ac­qui­si­tion comes 2 years af­ter Servi­er ac­quired Shire’s can­cer busi­ness for $2.4 bil­lion. They’ve been work­ing with Sym­phogen on a slate of pro­grams, in­clud­ing some favs – PD-1, LAG3 and TIM3 — where they are look­ing to dif­fer­en­ti­ate them­selves from the more promi­nent drugs in these nich­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.